Valuation : Dimerix Limited

Market Cap 165M 118M 102M 95.71M 87.37M 165M 11.32B 1.14B 443M 5.72B 445M 435M 18.95B P/E 2025
-24.3x
P/E 2026 -4.12x
Enterprise Value 149M 107M 92.23M 86.48M 78.94M 149M 10.23B 1.03B 400M 5.16B 402M 393M 17.12B EV / Sales 2025
49.4x
EV / Sales 2026 15.4x
Free-Float
77.77%
Yield 2025 *
-
Yield 2026 -
1 day-5.17%
1 week-11.29%
Current month+12.24%
1 month+14.58%
3 months+48.65%
6 months-42.11%
Current year-50.00%
1 week 0.28
Extreme 0.275
0.32
1 month 0.24
Extreme 0.24
0.33
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.06
Extreme 0.061
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 27/08/2018
Director of Finance/CFO 59 29/01/2026
Chief Tech/Sci/R&D Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 61 03/07/2015
Chairman - -
Director/Board Member - 27/08/2018
Date Insider Type Main position Quantity % Market Cap.
12/12/25 A Free

Chairman

100,000 0.0167%
12/12/25 A Free

Chairman

100,000 0.0167%
12/12/25 A Free

Director

100,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-5.17%-11.29%-38.89%+292.86% 118M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.90%-2.08%+67.16%+131.28% 27.47B
Weighted average by Cap. -1.70%-1.06%+96.22%+129.11%

Financials

2025 2026
Net sales 5.59M 4.01M 3.45M 3.24M 2.96M 5.57M 383M 38.42M 14.99M 193M 15.05M 14.72M 641M 6.98M 5.01M 4.31M 4.04M 3.69M 6.96M 478M 47.99M 18.72M 242M 18.8M 18.39M 801M
Net income -13.25M -9.51M -8.19M -7.68M -7.01M -13.21M -909M -91.13M -35.56M -459M -35.7M -34.92M -1.52B -29.81M -21.39M -18.43M -17.28M -15.78M -29.72M -2.04B -205M -80M -1.03B -80.31M -78.56M -3.42B
Net Debt -68.19M -48.92M -42.16M -39.52M -36.08M -67.97M -4.68B -469M -183M -2.36B -184M -180M -7.83B -15.92M -11.42M -9.84M -9.23M -8.42M -15.87M -1.09B -109M -42.72M -551M -42.89M -41.96M -1.83B
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
28/08/26 A$0.2750 -5.17% 572,986
27/08/26 A$0.2900 0.00% 710,477
26/08/26 A$0.2900 -7.94% 1,791,495
25/08/26 A$0.3150 +1.61% 587,104
24/08/26 A$0.3100 0.00% 696,317